Brazil Revises Stability Study Standards To Bring Companies More Certainty
Executive Summary
Brazil’s medicines regulator ANVISA intends to update its criteria for stability studies for medicines so as to bring them into line with ICH guidelines and give drug developers more certainty.
You may also be interested in...
Brazil/South Korea Move To ICH Driving Seat Raises Global Harmonization Expectations
Brazil and South Korea have been accepted as new regulatory members of the International Council for Harmonisation. This has raised expectations that ICH guidelines will gain full acceptance in both countries, making it easier for the global innovative pharmaceutical industry to market their products there.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.